GSK (LON:GSK) Share Price Passes Above 200-Day Moving Average – Time to Sell?

GSK plc (LON:GSK)’s share price crossed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of GBX 1,448.19 ($18.21) and traded as high as GBX 1,478.50 ($18.60). GSK shares last traded at GBX 1,467.50 ($18.46), with a volume of 16,677,213 shares changing hands.

Analyst Ratings Changes

Several research analysts have commented on GSK shares. Berenberg Bank dropped their price objective on shares of GSK from GBX 1,820 ($22.89) to GBX 1,600 ($20.12) and set a “buy” rating for the company in a research note on Friday, November 29th. JPMorgan Chase & Co. reiterated an “underweight” rating on shares of GSK in a research report on Tuesday, January 7th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and five have given a buy rating to the company’s stock. According to MarketBeat.com, GSK presently has an average rating of “Moderate Buy” and an average target price of GBX 1,805.83 ($22.71).

GSK Stock Up 0.4 %

The company has a debt-to-equity ratio of 114.64, a quick ratio of 0.73 and a current ratio of 0.81. The stock has a market cap of £59.55 billion, a P/E ratio of 23.71, a P/E/G ratio of 1.24 and a beta of 0.31. The firm has a 50 day simple moving average of GBX 1,391.65 and a two-hundred day simple moving average of GBX 1,447.40.

GSK (LON:GSK) last issued its quarterly earnings results on Wednesday, February 5th. The company reported GBX 23.20 ($0.29) earnings per share (EPS) for the quarter. GSK had a return on equity of 18.08% and a net margin of 8.02%. Equities research analysts predict that GSK plc will post 175.980975 earnings per share for the current year.

Insider Activity

In related news, insider Emma Walmsley sold 120,653 shares of GSK stock in a transaction that occurred on Monday, February 10th. The shares were sold at an average price of GBX 1,453 ($18.27), for a total value of £1,753,088.09 ($2,204,864.91). Also, insider Jonathan Symonds bought 1,500 shares of the firm’s stock in a transaction on Friday, December 20th. The shares were bought at an average cost of GBX 1,315 ($16.54) per share, for a total transaction of £19,725 ($24,808.20). 1.61% of the stock is owned by corporate insiders.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.